MAPT and Alzheimer disease: In vivo biomarkers using amyloid-positron emission tomography (PET) and tau-PET,1 as well as cerebrospinal fluid (CSF) assessments of Aβ and phosphorylated tau (pTau)2 can be used to identify core neuropathologic features of AD in living humans.